TW202342004A - Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid - Google Patents
Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid Download PDFInfo
- Publication number
- TW202342004A TW202342004A TW111149415A TW111149415A TW202342004A TW 202342004 A TW202342004 A TW 202342004A TW 111149415 A TW111149415 A TW 111149415A TW 111149415 A TW111149415 A TW 111149415A TW 202342004 A TW202342004 A TW 202342004A
- Authority
- TW
- Taiwan
- Prior art keywords
- ergothioneine
- docosahexaenoic acid
- docosahexaenoic
- salt
- acid
- Prior art date
Links
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title claims abstract description 259
- 235000020669 docosahexaenoic acid Nutrition 0.000 title claims abstract description 171
- 229940090949 docosahexaenoic acid Drugs 0.000 title claims abstract description 122
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 title claims abstract description 116
- 229940093497 ergothioneine Drugs 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 150000003839 salts Chemical class 0.000 title claims abstract description 72
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 25
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical class CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 31
- 229930195729 fatty acid Natural products 0.000 claims description 31
- 239000000194 fatty acid Substances 0.000 claims description 31
- 150000004665 fatty acids Chemical class 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000000470 constituent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000014102 seafood Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 235000013361 beverage Nutrition 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 235000021323 fish oil Nutrition 0.000 description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- -1 inorganic acid salts Chemical class 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 150000007513 acids Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 235000014593 oils and fats Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000003925 brain function Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- MAMJNXVNGGBHFN-UHFFFAOYSA-N docosa-1,3,5,7,9,11-hexaene Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC=C MAMJNXVNGGBHFN-UHFFFAOYSA-N 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 244000251953 Agaricus brunnescens Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- 235000007710 Grifola frondosa Nutrition 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 240000002769 Morchella esculenta Species 0.000 description 2
- 235000002779 Morchella esculenta Nutrition 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 241000222350 Pleurotus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 159000000011 group IA salts Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- NIONDZDPPYHYKY-UHFFFAOYSA-N 2-hexenoic acid Chemical compound CCCC=CC(O)=O NIONDZDPPYHYKY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000222455 Boletus Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 241001135744 Colwellia Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- VWCDKQVEOINBJR-UHFFFAOYSA-N hex-2-enoic acid Chemical compound C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O VWCDKQVEOINBJR-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本發明係關於含有麥角硫因或其鹽及至少1種二十二碳六烯酸類之經口組成物。此外，本發明係關於至少1種二十二碳六烯酸類的使用，其係用於抑制源自麥角硫因或其鹽之苦味。再者，本發明係關於抑制源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味之方法。The present invention relates to an oral composition containing ergothioneine or a salt thereof and at least one docosahexaenoic acid. Furthermore, the present invention relates to the use of at least one docosahexaenoic acid for suppressing bitterness derived from ergothioneine or its salt. Furthermore, the present invention relates to a method for suppressing bitter taste derived from ergothioneine or its salt and odor derived from docosahexaenoic acids.
麥角硫因為親水性含硫胺基酸之一，已知具有以抗氧化能力為首之多樣的生理活性。關於麥角硫因的生理活性，例如，在專利文獻1中，已報導免疫應答活化細胞介素產生促進作用等。 由於麥角硫因具有多樣的生理活性，故近年來係作為食品用、化妝品用或醫藥用而受到矚目。 Ergothionea is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant capacity. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports that it has an immune response-activating interleukin production-promoting effect. Since ergothioneine has various physiological activities, it has attracted attention in recent years as a food, cosmetic or medicinal use.
另一方面，已知屬於鯖魚、秋刀魚、沙丁魚等青魚的魚油中所包含之油脂的脂肪酸成分之二十二碳六烯酸(以下亦稱為DHA)亦具有許多生理活性。關於含有DHA之組成物，例如，在專利文獻2中，已揭示含有DHA、辣椒紅素、葉黃素及玉米黃素之腦機能改善用內服組成物。 [先前技術文獻] [專利文獻] On the other hand, it is known that docosahexaenoic acid (hereinafter also referred to as DHA), a fatty acid component of oil contained in fish oil of herrings such as mackerel, saury, and sardines, also has many physiological activities. Regarding compositions containing DHA, for example, Patent Document 2 discloses an oral composition for improving brain function containing DHA, capsanthin, lutein, and zeaxanthin. [Prior technical literature] [Patent Document]
[專利文獻1]日本專利特開2017-218431號公報 [專利文獻2]日本專利第6375296號公報 [Patent Document 1] Japanese Patent Application Laid-Open No. 2017-218431 [Patent Document 2] Japanese Patent No. 6375296
[發明所欲解決之課題][Problem to be solved by the invention]
如上述，由於麥角硫因具有有用的生理活性，因而包含麥角硫因或其鹽之補充品等食品係有用於維持或增進健康。然而，麥角硫因或其鹽有獨特的味道，特定而言，刺舌之令人不快的苦味(bitterness)，在作為經口組成物之方面有改善之餘地。 此外，包含DHA之補充品等食品亦同樣地有用，但會有DHA或其衍生物有令人不快的味道(臭味)之問題，在作為經口組成物之方面仍有改善之餘地。 因此，儘管對含有麥角硫因或其鹽及二十二碳六烯酸類之經口組成物可期待各式各樣有用的效果，但一般認為會產生苦味的問題及臭味的問題。 As mentioned above, since ergothioneine has useful physiological activities, foods such as supplements containing ergothioneine or its salts are useful for maintaining or improving health. However, ergothioneine or its salts have a unique taste, specifically an unpleasant bitterness that is harsh on the tongue, and there is room for improvement as an oral composition. In addition, foods such as supplements containing DHA are equally useful, but there is a problem that DHA or its derivatives have an unpleasant taste (odor), and there is still room for improvement as an oral composition. Therefore, although various useful effects can be expected from oral compositions containing ergothioneine or its salts and docosahexaenoic acids, it is generally believed that problems with bitterness and odor may occur.
本發明之目的為提供源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味減低之含有麥角硫因或其鹽及至少1種二十二碳六烯酸類之經口組成物。此外，本發明之目的為提供至少1種二十二碳六烯酸類的使用，其係用於抑制源自麥角硫因或其鹽之苦味。再者，本發明之目的為提供抑制含有麥角硫因或其鹽及至少1種二十二碳六烯酸類之經口組成物中之源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味之方法。 [解決課題之手段] The object of the present invention is to provide a product containing ergothioneine or a salt thereof and at least one docosahexaene with reduced bitterness derived from ergothioneine or its salts and odor derived from docosahexaenoic acids. Oral composition of acids. Furthermore, an object of the present invention is to provide the use of at least one docosahexaenoic acid for suppressing bitterness derived from ergothioneine or its salt. Furthermore, an object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and at least one docosahexaenoic acid, which suppresses the bitterness and taste derived from ergothioneine or a salt thereof. Methods for the odor of docosahexaenoic acids. [Means to solve the problem]
本發明者等人為了解決上述課題而致力研究之結果，發現若以特定的重量比將麥角硫因或其鹽及至少1種二十二碳六烯酸類進行組合，則可有效地抑制源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味。As a result of the inventors' efforts to solve the above-mentioned problems, they found that if ergothioneine or its salt and at least one kind of docosahexaenoic acid are combined in a specific weight ratio, the source of the source can be effectively suppressed. The bitter taste comes from ergothioneine or its salts and the odor comes from docosahexaenoic acids.
本發明含括以下經口組成物等。 [1]一種經口組成物，其含有下述成分(A)及(B)：(A)麥角硫因或其鹽，及(B)至少1種二十二碳六烯酸類，成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))為1～95。 [2]如上述[1]所記載之組成物，其中，上述二十二碳六烯酸類係選自由游離的二十二碳六烯酸、其鹽及在構成脂肪酸中包含二十二碳六烯酸之化合物所組成之群組。 [3]如上述[2]所記載之組成物，其中，上述在構成脂肪酸中包含二十二碳六烯酸之化合物係選自由構成脂肪酸的一部分或全部為二十二碳六烯酸之三甘油酯、構成脂肪酸的一部分或全部為二十二碳六烯酸之二甘油酯、構成脂肪酸為二十二碳六烯酸之單甘油酯、構成脂肪酸的一部分或全部為二十二碳六烯酸之磷脂質、構成脂肪酸的一部分或全部為二十二碳六烯酸之醣脂質及二十二碳六烯酸的醇酯所組成之群組。 [4]如上述[1]～[3]中任一項所記載之組成物，其中，成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))為5～60。 [5]如上述[1]～[4]中任一項所記載之組成物，其中，成分(B)係源自魚介類。 [6]如上述[1]～[5]中任一項所記載之組成物，其係飲食品。 [7]一種至少1種二十二碳六烯酸類的使用，其係用於抑制源自麥角硫因或其鹽之苦味。 [8]一種抑制源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味之方法，其係在含有(A)麥角硫因或其鹽及(B)至少1種二十二碳六烯酸類之經口組成物的調製中，將成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))調整成1～95。 [發明效果] The present invention includes the following oral compositions and the like. [1] An oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one docosahexaenoic acid, the component ( The weight ratio ((B)/(A)) of B) (docosahexaenoic acid conversion) to component (A) (ergothioneine conversion) is 1 to 95. [2] The composition according to the above [1], wherein the docosahexaenoic acid is selected from free docosahexaenoic acid, its salts, and docosahexaenoic acid contained in the constituent fatty acids. A group of olefinic acid compounds. [3] The composition according to the above [2], wherein the compound containing docosahexaenoic acid in the constituting fatty acid is selected from the group consisting of three compounds in which a part or all of the constituting fatty acid is docosahexaenoic acid. Glyceride, diglyceride in which a part or all of the fatty acid is docosahexaenoic acid, monoglyceride in which a fatty acid is docosahexaenoic acid, part or all of the fatty acid is docosahexaene A group consisting of acid phospholipids, glycolipids in which part or all of the fatty acid is docosahexaenoic acid, and alcohol esters of docosahexaenoic acid. [4] The composition according to any one of the above [1] to [3], wherein the component (B) (docosahexaenoic acid equivalent) is larger than the component (A) (ergothioneine equivalent). ), the weight ratio ((B)/(A)) is 5 to 60. [5] The composition according to any one of the above [1] to [4], wherein the component (B) is derived from fish and seafood. [6] The composition according to any one of the above [1] to [5], which is a food or drink. [7] Use of at least one docosahexaenoic acid for suppressing bitterness derived from ergothioneine or its salt. [8] A method of suppressing bitter taste derived from ergothioneine or its salt and odor derived from docosahexaenoic acids, which method contains (A) ergothioneine or its salt and (B) In the preparation of an oral composition of at least one docosahexaenoic acid, the weight ratio of component (B) (converted to docosahexaenoic acid) to component (A) (converted to ergothioneine) ((B)/(A)) is adjusted from 1 to 95. [Effects of the invention]
根據本發明，可提供源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味減低之含有麥角硫因或其鹽及至少1種二十二碳六烯酸類之經口組成物。此外，根據本發明，可提供至少1種二十二碳六烯酸類的使用，其係用於抑制源自麥角硫因或其鹽之苦味。再者，根據本發明，可提供抑制含有麥角硫因或其鹽及至少1種二十二碳六烯酸類之經口組成物中之源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味之方法。According to the present invention, the bitter taste derived from ergothioneine or its salt and the odor derived from docosahexaenoic acid can be provided, which contains ergothioneine or its salt and at least one docosahexaene. Oral composition of acids. Furthermore, according to the present invention, the use of at least one docosahexaenoic acid for suppressing bitterness derived from ergothioneine or its salt can be provided. Furthermore, according to the present invention, it is possible to provide an oral composition containing ergothioneine or a salt thereof and at least one docosahexaenoic acid, which suppresses the bitterness and taste derived from ergothioneine or a salt thereof. Methods for the odor of docosahexaenoic acids.
本發明之經口組成物(以下亦稱為「本發明之組成物」)含有下述成分(A)及(B)：(A)麥角硫因或其鹽，及(B)至少1種二十二碳六烯酸類，成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))為1～95。The oral composition of the present invention (hereinafter also referred to as the "composition of the present invention") contains the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one of Docosahexaenoic acids, the weight ratio ((B)/(A)) of component (B) (converted to docosahexaenoic acid) to component (A) (converted to ergothioneine) is 1 to 95.
麥角硫因為含硫胺基酸的一種。在本發明中，麥角硫因較佳為L-麥角硫因。 作為麥角硫因的鹽，只要是藥理學上可容許的鹽或飲食品上可容許的鹽，即無特別限定，可為酸性鹽及鹼性鹽中之任何者。作為酸性鹽，可列舉例如鹽酸鹽、硫酸鹽、硝酸鹽、磷酸鹽等無機酸鹽；醋酸鹽、檸檬酸鹽、馬來酸鹽、蘋果酸鹽、草酸鹽、乳酸鹽、琥珀酸鹽、富馬酸鹽、丙酸鹽等有機酸鹽等。作為鹼性鹽，可列舉例如鈉鹽、鉀鹽等鹼金屬鹽；鈣鹽、鎂鹽等鹼土族金屬鹽等。 Ergothione is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt that is acceptable in foods and beverages, and it may be either an acidic salt or an alkaline salt. Examples of acidic salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; acetate, citrate, maleate, malate, oxalate, lactate, and succinate. , fumarate, propionate and other organic acid salts. Examples of the alkaline salt include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and the like.
麥角硫因或其鹽不受其形態或製造方法等任何限制。麥角硫因或其鹽可使用化學合成品，亦可使用從天然物中進行萃取及精製而得者。L-麥角硫因在屬於側耳科側耳屬的蕈菇之金頂側耳(Golden/Yellow Oyster Mushroom)(學名：Pleurotus cornucopiae var. citrinopileatus)中大量含有。L-麥角硫因亦包含在白鈕扣蘑菇、克里米尼蘑菇、波特貝拉(Portabella)蘑菇等雙孢蘑菇(學名：Agaricus bisporus)、平菇(Grey Oyster Mushroom)(學名：Pleurotus ostreatus)、香菇(學名：Lentinula edodes)、舞茸(學名：Grifola frondosa)、靈芝(學名：Ganoderma lucidum)、猴頭菇(學名：Hericium erinaceus)、柳松茸(學名：Agrocybe aegerita)、杏茸(學名：Cantharellus cibarius)、牛肝菌(學名：Boletus edulis)、羊肚菌(學名：Morchella esculenta)等蕈菇中。在從天然物中獲得L-麥角硫因之情況，較佳係從金頂側耳中進行萃取等。麥角硫因或其鹽亦可藉由微生物發酵予以製造。麥角硫因或其鹽亦可加以單離。Ergothioneine or its salts are not subject to any restrictions on their form or production method. Ergothioneine or its salt can be chemically synthesized or extracted and refined from natural products. L-ergothioneine is contained in large amounts in the Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom belonging to the genus Pleurotus. L-ergothioneine is also included in Agaricus bisporus (scientific name: Agaricus bisporus), Gray Oyster Mushroom (scientific name: Pleurotus ostreatus), such as white button mushrooms, crimini mushrooms, and Portabella mushrooms. ), shiitake mushrooms (scientific name: Lentinula edodes), maitake mushrooms (scientific name: Grifola frondosa), Ganoderma lucidum (scientific name: Ganoderma lucidum), Hericium erinaceus (scientific name: Hericium erinaceus), willow pine mushroom (scientific name: Agrocybe aegerita), apricot mushroom (scientific name : Cantharellus cibarius), boletus (scientific name: Boletus edulis), morels (scientific name: Morchella esculenta) and other mushrooms. When L-ergothioneine is obtained from a natural product, it is preferable to extract it from Pleurotus aureus. Ergothioneine or its salts can also be produced by microbial fermentation. Ergothioneine or its salts can also be isolated.
本發明之組成物係藉由以上述比率含有麥角硫因或其鹽及至少1種二十二碳六烯酸類，而減低源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味。因此，麥角硫因或其鹽及二十二碳六烯酸類的持續攝取變得容易。The composition of the present invention contains ergothioneine or its salt and at least one docosahexaenoic acid in the above-mentioned ratio, thereby reducing the bitterness derived from ergothioneine or its salt and the bitter taste derived from docosahexaenoic acid. The odor of carbahexaenoic acids. Therefore, continuous intake of ergothioneine or its salts and docosahexaenoic acids becomes easy.
作為二十二碳六烯酸類，可使用二十二碳六烯酸(游離的二十二碳六烯酸)、其鹽及此等的衍生物。二十二碳六烯酸類可單獨使用1種，亦可組合使用2種以上。作為二十二碳六烯酸的衍生物，可利用例如具有鍵結有二十二碳六烯酸之結構之化合物，及能夠藉由水解分離出二十二碳六烯酸之化合物。作為能夠藉由水解分離出二十二碳六烯酸之化合物，可列舉在構成脂肪酸中包含二十二碳六烯酸之化合物。 本發明中所使用之二十二碳六烯酸類較佳係選自由游離的二十二碳六烯酸、其鹽及在構成脂肪酸中包含二十二碳六烯酸之化合物所組成之群組。 作為二十二碳六烯酸的鹽，可列舉例如鈣鹽、鈉鹽等。 作為在構成脂肪酸中包含二十二碳六烯酸之化合物，較佳為選自由構成脂肪酸的一部分或全部為二十二碳六烯酸之三甘油酯、構成脂肪酸的一部分或全部為二十二碳六烯酸之二甘油酯、構成脂肪酸為二十二碳六烯酸之單甘油酯、構成脂肪酸的一部分或全部為二十二碳六烯酸之磷脂質、構成脂肪酸的一部分或全部為二十二碳六烯酸之醣脂質及二十二碳六烯酸的醇酯所組成之群組之化合物。 在該等之中，作為二十二碳六烯酸類，更佳為構成脂肪酸的一部分或全部為二十二碳六烯酸之三甘油酯、二甘油酯及磷脂質，再佳為構成脂肪酸的一部分或全部為二十二碳六烯酸之三甘油酯及二甘油酯，特佳為構成脂肪酸的一部分或全部為二十二碳六烯酸之三甘油酯。 As docosahexaenoic acids, docosahexaenoic acid (free docosahexaenoic acid), salts thereof, and derivatives thereof can be used. Docosahexaenoic acid may be used individually by 1 type, and may be used in combination of 2 or more types. As derivatives of docosahexaenoic acid, for example, compounds having a structure in which docosahexaenoic acid is bonded and compounds capable of isolating docosahexaenoic acid by hydrolysis can be used. Examples of compounds from which docosahexaenoic acid can be separated by hydrolysis include compounds containing docosahexaenoic acid in its constituent fatty acids. The docosahexaenoic acids used in the present invention are preferably selected from the group consisting of free docosahexaenoic acid, salts thereof, and compounds containing docosahexaenoic acid in constituting fatty acids. . Examples of salts of docosahexaenoic acid include calcium salts, sodium salts, and the like. The compound containing docosahexaenoic acid in the constituting fatty acid is preferably selected from the group consisting of triglyceride in which part or all of the constituting fatty acid is docosahexaenoic acid, and a compound in which part or all of the constituting fatty acid is docosahexaenoic acid. Diglyceride of carbohexaenoic acid, monoglyceride of which the fatty acid is docosahexaenoic acid, phospholipids where part or all of the fatty acid is docosahexaenoic acid, part or all of the fatty acid is diglyceride Compounds of the group consisting of glycolipids of docosahexaenoic acid and alcohol esters of docosahexaenoic acid. Among these, as the docosahexaenoic acid, a part or all of the docosahexaenoic acid triglyceride, diglyceride, and phospholipid constituting the fatty acid is more preferable, and a further preferable one is one constituting the fatty acid. Part or all of them are triglycerides and diglycerides of docosahexaenoic acid, and particularly preferably part or all of the fatty acids are triglycerides of docosahexaenoic acid.
本發明中所使用之二十二碳六烯酸類不受其形態或製造方法等任何限制，可使用化學合成品，亦可使用源自於天然物者或源自於基因重組生物(大腸菌、酵母、植物等)者。作為源自於天然物者，可列舉源自於具有生產DHA之能力之魚介類或藻類、菌類(科爾韋氏菌(Colwellia)屬細菌、盤蜷綱(Labyrinthulea)類等)、植物(地錢等)者。在該等之中，二十二碳六烯酸類較佳係源自魚介類。 此外，可使用從含有二十二碳六烯酸類之天然物等原料中進行萃取及／或精製而得之二十二碳六烯酸類，亦可依原樣使用該原料而使二十二碳六烯酸類含在組成物中。作為包含二十二碳六烯酸類之原料，可列舉例如從魚油、肉類、乳類中所萃取出之油脂等食用油脂。作為包含二十二碳六烯酸類之魚油，較佳為以二十二碳六烯酸類(二十二碳六烯酸換算)的含有率成為5重量%以上，較佳為10重量%以上，更佳為50重量%以上之方式進行濃縮而得之魚油。例如，可使用從含有二十二碳六烯酸類之魚油中進行萃取及／或精製而得之二十二碳六烯酸類，亦可依原樣使用該魚油。在一態樣中，本發明之經口組成物含有魚油，二十二碳六烯酸類亦可為該魚油的一部分。 The docosahexaenoic acid used in the present invention is not subject to any restrictions on its form or production method, and can be chemically synthesized, naturally derived, or derived from genetically recombinant organisms (coliform bacteria, yeast, etc.) , plants, etc.). Examples of those derived from natural products include fish, algae, fungi (bacteria of the genus Colwellia, Labyrinthulea, etc.) that have the ability to produce DHA, and plants (terrestrial organisms). money, etc.). Among these, docosahexaenoic acids are preferably derived from fish. In addition, docosahexaenoic acid extracted and/or purified from raw materials such as natural products containing docosahexaenoic acid can be used, or the raw material can be used as it is to make docosahexaenoic acid Alkenoic acids are included in the composition. Examples of raw materials containing docosahexaenoic acids include edible oils and fats such as oils and fats extracted from fish oil, meat, and dairy products. As for the fish oil containing docosahexaenoic acid, it is preferable that the content rate of docosahexaenoic acid (docosahexaenoic acid conversion) is 5 weight% or more, and it is more preferable that it is 10 weight% or more. More preferably, the fish oil is concentrated to 50% by weight or more. For example, docosahexaenoic acid extracted and/or purified from fish oil containing docosahexaenoic acid can be used, or the fish oil can be used as it is. In one aspect, the oral composition of the present invention contains fish oil, and docosahexaenoic acid may also be a part of the fish oil.
在本發明之組成物中，成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))為1～95。若上述重量比為上述範圍，則可抑制源自成分(A)之苦味。此外，亦可抑制源自成分(B)之臭味。藉此，組成物變得易於攝取。上述重量比較佳為3～70，更佳為5～60，再佳為5～50。 本說明書中，麥角硫因換算的量或與其類似的表達方式，在成分(A)為麥角硫因之情況，係意味其量，在成分(A)為麥角硫因的鹽之情況，係意味該鹽的莫耳數乘以麥角硫因的分子量所獲得之值。 二十二碳六烯酸換算的量或與其類似的表達方式，在成分(B)為游離的DHA之情況，係意味其量，在成分(B)非為游離的DHA之情況，係意味藉由皂化處理或酵素處理使DHA游離，就游離的DHA而言所換算而得之量。在含有2種以上二十二碳六烯酸類之情況，係此等的合計。 In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) (docosahexaenoic acid conversion) to component (A) (ergothioneine conversion) is 1 to 95. If the said weight ratio is in the said range, the bitter taste originating from component (A) can be suppressed. In addition, the odor originating from component (B) can also be suppressed. Thereby, the composition becomes easy to ingest. The above-mentioned weight ratio is preferably 3 to 70, more preferably 5 to 60, and still more preferably 5 to 50. In this specification, the amount of ergothioneine converted or expressions similar to it mean the amount when ingredient (A) is ergothioneine, and when ingredient (A) is a salt of ergothioneine , means the value obtained by multiplying the molar number of the salt by the molecular weight of ergothioneine. The amount converted from docosahexaenoic acid or expressions similar to it means the amount when ingredient (B) is free DHA, and means the amount when ingredient (B) is not free DHA. The amount of DHA that is freed by saponification or enzyme treatment, and converted into free DHA. When two or more docosahexaenoic acids are contained, it is the total of these.
本發明之組成物中所包含之麥角硫因或其鹽的含量並無特別限定，可因應其形態等而設定。 本發明之組成物中之麥角硫因或其鹽的含量以麥角硫因換算，係例如在該組成物中較佳為0.1重量%以上，更佳為0.5重量%以上，再佳為1重量%以上，此外，較佳為50重量%以下，更佳為20重量%以下，再佳為10重量%以下。在一態樣中，麥角硫因或其鹽的含量以麥角硫因換算，係在本發明之組成物中較佳為0.1～50重量%，更佳為0.5～20重量%，再佳為1～10重量%。 麥角硫因的含量可藉由高效液相層析(HPLC)法予以測定。 The content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited and can be set according to its form, etc. The content of ergothioneine or its salt in the composition of the present invention is, for example, preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and still more preferably 1% in terms of ergothioneine. The content is preferably 50% by weight or less, more preferably 20% by weight or less, and still more preferably 10% by weight or less. In one aspect, the content of ergothioneine or its salt in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.5 to 20% by weight, even more preferably in terms of ergothioneine. It is 1~10% by weight. The content of ergothioneine can be determined by high performance liquid chromatography (HPLC).
本發明之組成物中所包含之二十二碳六烯酸類的含量並無特別限定，可因應其形態等而設定。 在含有2種以上二十二碳六烯酸類之情況，上述含量為此等的合計含量。二十二碳六烯酸的含量可藉由氣相層析(GC)法予以測定。 The content of docosahexaenoic acids contained in the composition of the present invention is not particularly limited and can be set according to its form, etc. When two or more types of docosahexaenoic acids are contained, the above-mentioned content is the total content of these. The content of docosahexaenoic acid can be determined by gas chromatography (GC).
就本發明之組成物而言，麥角硫因或其鹽的含量係成人的每1日攝取量以麥角硫因換算較佳為1～100mg，更佳為2～50mg，再佳為5～25mg，特佳為5～20mg。 就本發明之組成物而言，二十二碳六烯酸類的含量係成人的每1日攝取量以二十二碳六烯酸換算較佳為100～2500mg，更佳為150～1000mg，再佳為200～500mg。 In the composition of the present invention, the content of ergothioneine or its salt is the daily intake of an adult in terms of ergothioneine. It is preferably 1 to 100 mg, more preferably 2 to 50 mg, and still more preferably 5 ~25mg, especially 5~20mg. In the composition of the present invention, the content of docosahexaenoic acid is preferably 100 to 2500 mg, more preferably 150 to 1000 mg in terms of docosahexaenoic acid per day intake for an adult. The optimal dosage is 200~500mg.
麥角硫因或其鹽及二十二碳六烯酸類為包含在天然物或飲食品中且有食用經驗之化合物。因此，從安全性之觀點而言，一般認為麥角硫因或其鹽及二十二碳六烯酸類在例如每日攝取上問題較少。根據本發明，可提供安全性較高，且源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味減低而易於攝取之組成物。Ergothioneine or its salts and docosahexaenoic acids are compounds that are contained in natural products or foods and drinks and have been consumed. Therefore, from the viewpoint of safety, it is generally considered that ergothioneine or its salts and docosahexaenoic acids are less problematic in terms of daily intake, for example. According to the present invention, it is possible to provide a composition that is highly safe and has reduced bitterness derived from ergothioneine or its salts and odor derived from docosahexaenoic acids, making it easy to ingest.
如上述，已知麥角硫因或其鹽發揮多樣的生理活性或健康機能，例如，已知抗氧化作用、腦機能改善效果、抗老化作用、眼疾患改善效果、美白效果、紫外線吸收效果、黑色素產生抑制效果、活性氧種的消除作用、彈性蛋白酶活性阻礙效果、皺紋形成抑制效果、肌膚鬆弛抑制效果、自噬促進效果等。 因此，本發明之組成物可適合地用於抗氧化、用於改善腦機能、用於抗老化、用於眼疾患、用於美白、用於吸收紫外線、用於抑制黑色素產生、用於消除活性氧種、用於阻礙彈性蛋白酶活性、用於抑制皺紋形成、用於抑制肌膚鬆弛、用於促進自噬等。 As mentioned above, ergothioneine or its salts are known to exert various physiological activities or health functions. For example, they are known to have antioxidant effects, brain function improving effects, anti-aging effects, eye disease improving effects, whitening effects, and ultraviolet absorbing effects. Melanin production inhibitory effect, reactive oxygen species elimination effect, elastase activity inhibitory effect, wrinkle formation inhibitory effect, skin sagging inhibitory effect, autophagy promotion effect, etc. Therefore, the composition of the present invention can be suitably used for antioxidant, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for inhibiting melanin production, and for eliminating activity Oxygen species is used to hinder elastase activity, inhibit wrinkle formation, inhibit skin sagging, promote autophagy, etc.
針對二十二碳六烯酸類，已知會發揮腦機能改善效果、血中中性脂肪減低效果、抗過敏效果等多種健康機能。 由於本發明之組成物含有二十二碳六烯酸類，故亦可為了獲得由二十二碳六烯酸類所發揮之上述效果而使用。 Docosahexaenoic acid is known to exert various health functions such as brain function improvement effect, blood neutral fat reduction effect, and anti-allergic effect. Since the composition of the present invention contains docosahexaenoic acids, it can also be used to obtain the above effects exerted by docosahexaenoic acids.
本發明之組成物可應用於治療性用途(醫療用途)或非治療性用途(非醫療用途)中之任何者。所謂非治療性，係不包含醫療行為，即人類的手術、治療或診斷之概念。 本發明之組成物可製成飲食品、醫藥品、醫藥部外品、飼料等形態。本發明之組成物亦可為摻合至飲食品、醫藥品、醫藥部外品、飼料等中而使用之素材或製劑等。 The composition of the present invention can be used in any of therapeutic use (medical use) or non-therapeutic use (non-medical use). The so-called non-therapeutic does not include the concept of medical behavior, that is, human surgery, treatment or diagnosis. The composition of the present invention can be made into the form of foods, beverages, pharmaceuticals, quasi-drugs, feed, etc. The composition of the present invention may also be a material or preparation that is blended into foods, beverages, pharmaceuticals, quasi-drugs, feeds, etc. and used.
本發明之組成物為經口用組成物，作為經口組成物，具體而言，可列舉飲食品、經口用醫藥品、醫藥部外品、飼料等，較佳為飲食品或經口用醫藥品，更佳為飲食品。The composition of the present invention is a composition for oral use. Specific examples of the composition for oral use include food and beverages, pharmaceuticals for oral use, quasi-drugs, feeds, etc. Preferably, they are food, drink, or oral use. Pharmaceuticals, preferably food and beverages.
本發明之組成物在無損本發明的效果之前提下，除了麥角硫因或其鹽及二十二碳六烯酸類以外，尚可含有任意的添加劑、任意的成分。此等添加劑及成分可因應組成物的形態等而選擇，可使用一般能夠使用於飲食品、醫藥品、醫藥部外品、飼料等經口組成物者。The composition of the present invention may contain any additives and components in addition to ergothioneine or its salts and docosahexaenoic acids without impairing the effects of the present invention. These additives and ingredients can be selected according to the form of the composition, etc., and those that can be generally used in oral compositions such as food and beverages, pharmaceuticals, quasi-drugs, and feeds can be used.
在本發明之組成物中，亦可添加例如含有二十二碳六烯酸以外之脂肪酸之油脂或不含二十二碳六烯酸類之油脂。 在本發明之組成物含有油脂之情況，較佳係構成油脂之全脂肪酸之中，DHA的重量比例較佳為5重量%以上，更佳為10重量%以上，再佳為20重量%以上，特佳為30重量%以上。 構成油脂之全脂肪酸之中，針對n-3系(ω3系)脂肪酸，較佳係DHA的重量比例最高。 For example, oils and fats containing fatty acids other than docosahexaenoic acid or oils and fats containing no docosahexaenoic acid may be added to the composition of the present invention. When the composition of the present invention contains oil and fat, the weight proportion of DHA among the total fatty acids constituting the oil and fat is preferably 5% by weight or more, more preferably 10% by weight or more, and still more preferably 20% by weight or more. Particularly preferred is 30% by weight or more. Among the total fatty acids constituting fats and oils, among n-3 series (ω3 series) fatty acids, the preferred series DHA has the highest weight ratio.
本發明之組成物的製造方法並無特別限定，例如，可將(A)麥角硫因或其鹽及(B)至少1種二十二碳六烯酸類以此等的重量比成為上述範圍之方式進行摻合而予以製造。藉由在含有(A)麥角硫因或其鹽及(B)至少1種二十二碳六烯酸類之經口組成物的調製中，將成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))調整成1～95，便可獲得源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味受到抑制之經口組成物。上述重量比的調整可藉由例如添加成分(A)及／或成分(B)而施行。 在上述製造方法中，麥角硫因或其鹽、二十二碳六烯酸類、此等的較佳態樣係與上述之本發明之組成物相同。此外，成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比或使用量的較佳範圍亦與本發明之組成物中之成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比或使用量的較佳範圍相同。 在一態樣中，在經口組成物的製造中，亦可摻合上述包含二十二碳六烯酸類之魚油。二十二碳六烯酸類亦可其一部分或全部作為魚油的一部分摻合至組成物中。 The method of producing the composition of the present invention is not particularly limited. For example, (A) ergothioneine or a salt thereof and (B) at least one docosahexaenoic acid may be used in such a weight ratio that it falls within the above range. blended and manufactured. By preparing an oral composition containing (A) ergothioneine or a salt thereof and (B) at least one docosahexaenoic acid, component (B) (docosahexaenoic acid Conversion) The weight ratio ((B)/(A)) relative to ingredient (A) (conversion of ergothioneine) is adjusted to 1 to 95, and the bitterness and taste derived from ergothioneine or its salt can be obtained. Oral composition that suppresses the odor of docosahexaenoic acids. The above-mentioned adjustment of the weight ratio can be performed, for example, by adding component (A) and/or component (B). In the above-mentioned production method, preferred aspects of ergothioneine or its salts, docosahexaenoic acids, and the like are the same as the above-mentioned composition of the present invention. In addition, the preferred range of the weight ratio or usage amount of component (B) (converted as docosahexaenoic acid) relative to component (A) (converted as ergothioneine) is also consistent with the component (converted in terms of ergothioneine) in the composition of the present invention. The preferable ranges of the weight ratio or usage amount of B) (docosahexaenoic acid conversion) with respect to component (A) (ergothioneine conversion) are the same. In one aspect, the above-mentioned fish oil containing docosahexaenoic acid may be blended in the production of an oral composition. A part or all of the docosahexaenoic acids may be blended into the composition as part of the fish oil.
在將本發明之組成物製成飲食品、醫藥品、醫藥部外品、飼料等之情況，其製造方法並無特別限定，可藉由一般的方法予以製造。在一態樣中，本發明之組成物亦可由麥角硫因或其鹽及二十二碳六烯酸類所組成。本發明之經口組成物的形態並無特別限定，可為固體狀(粉末狀、顆粒狀、錠狀等)、液狀、糊狀等。When the composition of the present invention is made into foods, drinks, pharmaceuticals, quasi-drugs, feeds, etc., the production method is not particularly limited and can be produced by a general method. In one aspect, the composition of the present invention may also be composed of ergothioneine or its salt and docosahexaenoic acid. The form of the oral composition of the present invention is not particularly limited and may be solid (powder, granular, tablet, etc.), liquid, paste, etc.
例如，在將本發明之組成物製成飲食品之情況，可在麥角硫因或其鹽及二十二碳六烯酸類中摻合能夠使用於飲食品之成分(例如食品素材、視需要使用之食品添加物等)，製成多種飲食品。飲食品並無特別限定，可列舉例如一般的飲食品、健康食品、健康輔助食品、健康飲料、機能性標示食品、特定保健用食品、病者用飲食品等。上述健康食品、健康輔助食品、機能性標示食品、特定保健用食品等可製成例如細粒劑、錠劑、顆粒劑、散劑、膠囊劑、嚼錠劑、乾糖漿劑、糖漿劑、液劑、飲料、飲劑、流質食物等各種製劑型態而使用。For example, when the composition of the present invention is made into food and drink, ergothioneine or its salt and docosahexaenoic acid may be mixed with ingredients that can be used in food and drink (such as food materials, if necessary). Use food additives, etc.) to make a variety of food and drink products. Food and beverages are not particularly limited, and examples thereof include general food and beverages, health foods, health supplements, health drinks, foods with functional labels, foods for specific health uses, and foods and beverages for patients. The above-mentioned health food, health supplement food, food with functional labeling, food for specific health use, etc. can be prepared into fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, and liquids. It is used in various preparation types such as beverages, beverages, and liquid foods.
在將本發明之組成物製成醫藥品或醫藥部外品之情況，可例如在麥角硫因或其鹽及二十二碳六烯酸類中摻合藥理學上可容許的載體、視需要添加之添加劑等，製成各種劑型的醫藥品或醫藥部外品。該種載體、添加劑等只要是能夠使用於醫藥品或醫藥部外品且藥理學上可容許者即可，可列舉例如賦形劑、黏合劑、崩解劑、潤滑劑、抗氧化劑、著色劑等中之1種或2種以上。作為醫藥品或醫藥部外品的用於經口投予之劑型，可列舉液劑、錠劑、散劑、細粒劑、顆粒劑、糖衣錠、膠囊劑、懸浮液、乳劑、嚼錠劑等。When the composition of the present invention is made into a pharmaceutical or quasi-drug, for example, ergothioneine or a salt thereof and docosahexaenoic acid may be blended with a pharmacologically acceptable carrier, if necessary. Additives, etc., are added to produce pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, etc. can be used as long as they can be used in pharmaceuticals or quasi-drugs and are pharmacologically acceptable. Examples include excipients, binders, disintegrants, lubricants, antioxidants, and colorants. 1 or more of the above. Dosage forms for oral administration as pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, and the like.
在將本發明之組成物製成飼料之情況，只要將麥角硫因或其鹽及二十二碳六烯酸類摻合至飼料中即可。在飼料中，亦包含飼料添加劑。作為飼料，可列舉例如用於牛、豬、雞、羊、馬等之家畜用飼料；用於兔、大鼠、小鼠等之小動物用飼料；用於犬、貓、小鳥等之寵物食品等。When the composition of the present invention is made into feed, ergothioneine or its salt and docosahexaenoic acid may be blended into the feed. Feed additives are also included in the feed. Examples of the feed include feeds for cattle, pigs, chickens, sheep, horses, etc.; feeds for small animals such as rabbits, rats, mice, etc.; and pet foods for dogs, cats, birds, etc. .
攝取或投予本發明之組成物之對象(亦可稱為投予對象)並無特別限定。較佳為人類或非人類哺乳動物，更佳為人類。The subjects who ingest or administer the composition of the present invention (which may also be referred to as administration subjects) are not particularly limited. Preferably it is a human or non-human mammal, more preferably a human being.
本發明亦含括以下方法。 一種抑制源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之臭味之方法，其係在含有(A)麥角硫因或其鹽及(B)至少1種二十二碳六烯酸類之經口組成物的調製中，將成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比((B)／(A))調整成1～95。 藉由上述方法，便能夠有效地抑制源自麥角硫因或其鹽之苦味及源自二十二碳六烯酸類之令人不快的味道(臭味)。 The present invention also encompasses the following methods. A method for suppressing bitter taste derived from ergothioneine or its salt and odor derived from docosahexaenoic acids, which method contains (A) ergothioneine or its salt and (B) at least one In the preparation of an oral composition of docosahexaenoic acid, the weight ratio of component (B) (converted to docosahexaenoic acid) to component (A) (converted to ergothioneine) ((B )/(A)) adjusted to 1~95. By the above method, the bitter taste derived from ergothioneine or its salt and the unpleasant taste (odor) derived from docosahexaenoic acid can be effectively suppressed.
本發明亦含括以下使用。 一種至少1種二十二碳六烯酸類的使用，其係用於抑制源自麥角硫因或其鹽之苦味。 在上述使用中，較佳係以至少1種二十二碳六烯酸類(二十二碳六烯酸換算)相對於麥角硫因或其鹽(麥角硫因換算)之重量比成為1～95之方式使用。 The invention also includes the following uses. The use of at least one docosahexaenoic acid for suppressing bitterness derived from ergothioneine or its salts. In the above use, it is preferable that the weight ratio of at least one docosahexaenoic acid (docosahexaenoic acid conversion) to ergothioneine or its salt (ergothioneine conversion) is 1 ~95 method to use.
在上述方法及使用中，麥角硫因或其鹽及二十二碳六烯酸類以及該等的較佳態樣係與上述之本發明之組成物相同。 此外，在上述方法及使用中，成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比或使用量的較佳範圍亦與本發明之組成物中之成分(B)(二十二碳六烯酸換算)相對於成分(A)(麥角硫因換算)之重量比或使用量的較佳範圍相同。 In the above methods and uses, ergothioneine or its salts and docosahexaenoic acids and their preferred aspects are the same as the above-mentioned composition of the present invention. In addition, in the above method and use, the preferred range of the weight ratio or usage amount of component (B) (converted to docosahexaenoic acid) relative to component (A) (converted to ergothioneine) is also consistent with the present invention. The preferred ranges of the weight ratio or usage amount of component (B) (docosahexaenoic acid conversion) relative to component (A) (ergothioneine conversion) in the composition are the same.
藉由上述方法及使用，便可抑制源自麥角硫因或其鹽之苦味及源自DHA之臭味，但亦可與其他苦味抑制方法及／或臭味抑制方法進行組合。 作為其他苦味抑制方法，可列舉例如在具有苦味之成分中添加甜味劑或矯味劑並加以製劑化之方法；將具有苦味之成分以糖衣被覆並加以製劑化之方法；或封入膠囊中並加以製劑化之方法等。 作為其他臭味抑制方法，可列舉例如將具有臭味之成分以糖衣被覆並加以製劑化之方法；封入膠囊中並加以製劑化之方法等。 By the above method and use, the bitter taste derived from ergothioneine or its salt and the odor derived from DHA can be suppressed, but it can also be combined with other bitter taste suppressing methods and/or odor suppressing methods. Other methods of suppressing bitterness include, for example, a method of adding a sweetener or a flavoring agent to a bitter component and formulating it; a method of coating a bitter component with a sugar coating and formulating it; or sealing it in a capsule and formulating it. Preparation methods, etc. Other odor suppressing methods include, for example, a method of coating an odorous component with a sugar coating and formulating it; a method of sealing it in a capsule and formulating it; and the like.
在本說明書中，由下限值及上限值所表示之數值範圍，即「下限值～上限值」，包含該等下限值及上限值。例如，由「1～2」所表示之範圍係意味1以上且2以下，包含1及2。在本說明書中，上限及下限可設為依據任何組合之範圍。 [實施例] In this specification, the numerical range represented by the lower limit value and the upper limit value, that is, "lower limit value ~ upper limit value", includes these lower limit values and upper limit values. For example, the range represented by “1 to 2” means 1 or more and 2 or less, and includes 1 and 2. In this specification, the upper and lower limits can be set as ranges based on any combination. [Example]
以下，基於實施例更具體地說明本發明。另外，本發明並不限定於此等實施例。Hereinafter, the present invention will be described in more detail based on examples. In addition, the present invention is not limited to these Examples.
下述評估試驗中所使用之材料係如下。 (A)麥角硫因：含有100%L-麥角硫因之原料 含有二十二碳六烯酸類之油脂：以二十二碳六烯酸換算含有50重量%二十二碳六烯酸類，且在構成脂肪酸之中，針對n-3系脂肪酸，DHA的重量比例最高之油脂 The materials used in the following evaluation tests are as follows. (A) Ergothioneine: raw material containing 100% L-ergothioneine Fats and oils containing docosahexaenoic acid: Containing 50% by weight of docosahexaenoic acid in terms of docosahexaenoic acid, and the weight ratio of DHA for n-3 fatty acids among the constituent fatty acids The highest fat
＜實施例1～3及比較例1～2：針對包含麥角硫因及二十二碳六烯酸類之經口組成物之味道評估試驗＞ 調製包含麥角硫因及二十二碳六烯酸類之經口組成物，3名熟習官能評估之品評員施行官能評估。 使用表1所示之量的上述(A)及含有二十二碳六烯酸類之油脂，調製實施例1～3及比較例1～2的經口組成物。將各經口組成物中之(A)麥角硫因及含有二十二碳六烯酸類之油脂的量、(B)二十二碳六烯酸類(二十二碳六烯酸換算)的含量、(B)二十二碳六烯酸類(二十二碳六烯酸換算)相對於(A)麥角硫因之重量比((B)／(A))示於表1。 各品評員將所調製而得之經口組成物的全量(例如，在比較例1中為20mg)直接置於舌上，依照以下基準評估源自麥角硫因之苦味的強度及源自二十二碳六烯酸類之臭味的強度。 <Examples 1 to 3 and Comparative Examples 1 to 2: Taste evaluation test of oral compositions containing ergothioneine and docosahexaenoic acids> An oral composition containing ergothioneine and docosahexaenoic acid was prepared, and three panelists familiar with sensory evaluation performed sensory evaluation. Oral compositions of Examples 1 to 3 and Comparative Examples 1 to 2 were prepared using the above-mentioned (A) and docosahexaenoic acid-containing fats and oils in the amounts shown in Table 1. The amount of (A) ergothioneine and docosahexaenoic acid-containing fats and oils in each oral composition, and (B) the amount of docosahexaenoic acid (docosahexaenoic acid conversion) Table 1 shows the content and the weight ratio ((B)/(A)) of (B) docosahexaenoic acids (docosahexaenoic acid conversion) to (A) ergothioneine. Each panelist placed the entire amount of the prepared oral composition (for example, 20 mg in Comparative Example 1) directly on the tongue, and evaluated the intensity of the bitter taste derived from ergothioneine and the bitter taste derived from ergothioneine based on the following criteria. The intensity of the odor of dodecahexaenoic acids.
(源自麥角硫因之苦味的評估基準) 依下述基準以1～5分(5個階段)進行評估。作為基準分，將使材料(A)(10mg)置於舌上之情況所感受到之源自麥角硫因之苦味的強度定為5分。 對3名品評員的評估進行統計，將平均值(分)示於表1。 在評估結果的平均值為4分以下之情況，評估為苦味受到抑制。 5分：強烈感受到源自麥角硫因之苦味 4分：感受到源自麥角硫因之苦味 3分：稍微感受到源自麥角硫因之苦味 2分：不怎麼感受到源自麥角硫因之苦味 1分：並未感受到源自麥角硫因之苦味 (Based on the evaluation of the bitterness of ergothioneine) Evaluate on a scale of 1 to 5 (5 levels) based on the following criteria. As a standard score, the intensity of the bitter taste derived from ergothioneine felt when material (A) (10 mg) is placed on the tongue is set as 5 points. The evaluations of the three tasters were statistically calculated, and the average values (points) are shown in Table 1. When the average value of the evaluation results is 4 points or less, it is evaluated that the bitter taste is suppressed. 5 points: The bitter taste derived from ergothioneine is strongly felt 4 points: Feel the bitter taste derived from ergothioneine 3 points: A slight bitter taste derived from ergothioneine 2 points: The bitter taste derived from ergothioneine is not felt very much. 1 point: No bitter taste derived from ergothioneine is felt
(源自二十二碳六烯酸類之臭味的評估基準) 依下述基準以1～5分(5個階段)進行評估。作為基準分，將使含有二十二碳六烯酸之油脂(10mg)置於舌上之情況所感受到之源自二十二碳六烯酸類之臭味的強度定為5分。 對3名品評員的評估進行統計，將平均值(分)示於表1。 在評估結果的平均值為4分以下之情況，評估為臭味受到抑制。 5分：強烈感受到源自二十二碳六烯酸類之臭味 4分：感受到源自二十二碳六烯酸類之臭味 3分：稍微感受到源自二十二碳六烯酸類之臭味 2分：不怎麼感受到源自二十二碳六烯酸類之臭味 1分：並未感受到源自二十二碳六烯酸類之臭味 (Evaluation criteria for odor derived from docosahexaenoic acid) Evaluate on a scale of 1 to 5 (5 levels) based on the following criteria. As a base score, the intensity of the odor originating from docosahexaenoic acid that is felt when oil and fat containing docosahexaenoic acid (10 mg) is placed on the tongue is set as 5 points. The evaluations of the three tasters were statistically calculated, and the average values (points) are shown in Table 1. When the average value of the evaluation results is 4 points or less, it is evaluated that the odor is suppressed. 5 points: The odor originating from docosahexaenoic acid is strongly felt 4 points: Feel the odor originating from docosahexaenoic acid 3 points: Slightly detectable odor originating from docosahexaenoic acid 2 points: The odor originating from docosahexaenoic acid is not very noticeable 1 point: No odor originating from docosahexaenoic acid was detected
＜結果＞ 已確認在僅麥角硫因之情況，會感受到源自麥角硫因之強烈的苦味，但若(A)麥角硫因與(B)二十二碳六烯酸類(二十二碳六烯酸換算)之重量比((B)／(A))為1～95的範圍內，則源自麥角硫因之苦味受到抑制。針對二十二碳六烯酸類，亦已確認就僅含有二十二碳六烯酸類之油脂而言，源自二十二碳六烯酸類之臭味強烈而難以攝取，但藉由以上述重量比與麥角硫因進行組合，源自二十二碳六烯酸類之臭味便受到抑制。 ＜Result＞ It has been confirmed that in the case of only ergothioneine, a strong bitter taste derived from ergothioneine is felt, but if (A) ergothioneine and (B) docosahexaenoic acid (docosahexaenoic acid) When the weight ratio ((B)/(A)) in terms of hexaenoic acid is in the range of 1 to 95, the bitter taste derived from ergothioneine is suppressed. Regarding docosahexaenoic acids, it has also been confirmed that oils and fats containing only docosahexaenoic acids have a strong odor derived from docosahexaenoic acids and are difficult to ingest. However, by taking the above weight When combined with ergothioneine, the odor originating from docosahexaenoic acids is suppressed.
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-209559 | 2021-12-23 | ||
| JP2021209559 | 2021-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202342004A true TW202342004A (en) | 2023-11-01 |
Family
ID=86902504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111149415A TW202342004A (en) | 2021-12-23 | 2022-12-22 | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN118450814A (en) |
| AU (1) | AU2022420208A1 (en) |
| TW (1) | TW202342004A (en) |
| WO (1) | WO2023120373A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0731417A (en) * | 1993-07-20 | 1995-02-03 | Health Eido:Kk | Encapsulated nutrient-assisting food |
| US20120128711A1 (en) * | 2009-09-21 | 2012-05-24 | Total Nutraceutical Solutions, Inc. | Anti-inflammatory approach to prevention and suppression of post-traumatic stress disorder, traumatic brain injury, depression and associated disease states |
| JP2012092085A (en) * | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| CA2877861A1 (en) * | 2012-06-26 | 2014-01-03 | Entia Biosciences, Inc. | A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
-
2022
- 2022-12-15 AU AU2022420208A patent/AU2022420208A1/en active Pending
- 2022-12-15 CN CN202280084275.0A patent/CN118450814A/en active Pending
- 2022-12-15 WO PCT/JP2022/046225 patent/WO2023120373A1/en active Application Filing
- 2022-12-22 TW TW111149415A patent/TW202342004A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022420208A1 (en) | 2024-06-20 |
| CN118450814A (en) | 2024-08-06 |
| WO2023120373A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2648266A1 (en) | Feed formulations containing docosahexaenoic acid | |
| TW202342004A (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid | |
| TW202342005A (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid | |
| TW202342006A (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and smell derived from arachidonic acids | |
| KR20240128887A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine or a salt thereof and odor derived from arachidonic acid | |
| KR20240128865A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine or its salt and odor derived from docosahexaenoic acid | |
| KR20240127368A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids | |
| WO2022230491A1 (en) | Composition for ameliorating or suppressing decline of kidney functions | |
| WO2024029393A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material | |
| WO2024172002A1 (en) | Vasodilation composition containing ergothioneine | |
| WO2022230486A1 (en) | Composition for promoting lipolysis | |
| TW202342009A (en) | Oral composition and method for minimizing bitter taste resulting from ergothioneine or salt thereof and odor resulting from vitamin E | |
| KR20240127427A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine | |
| WO2024172003A1 (en) | Ergothioneine-containing muscular atrophy suppressing composition and src tyrosine kinase inhibiting composition | |
| KR20240117147A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine and odor derived from grain oil or γ-oryzanol | |
| KR20240127364A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine or its salt and odor derived from vitamin E | |
| WO2024018955A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound | |
| TW202339725A (en) | Oral composition and method for suppressing bitterness derived from ergothioneine | |
| WO2024029392A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof | |
| WO2024018956A1 (en) | Oral composition, and method for suppressing bitterness originating from ergothioneine or salt thereof and odor originating from chondroitin sulfate or salt thereof | |
| WO2023120382A1 (en) | Oral composition and soft capsule agent | |
| KR20240127428A (en) | Oral compositions and soft capsules | |
| TW202322795A (en) | Composition containing sesamin and ergothioneine or salt thereof |